These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 32973794)

  • 41. Enhancing adoptive T cell immunotherapy with microRNA therapeutics.
    Ji Y; Hocker JD; Gattinoni L
    Semin Immunol; 2016 Feb; 28(1):45-53. PubMed ID: 26710685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.
    Dwyer CJ; Knochelmann HM; Smith AS; Wyatt MM; Rangel Rivera GO; Arhontoulis DC; Bartee E; Li Z; Rubinstein MP; Paulos CM
    Front Immunol; 2019; 10():263. PubMed ID: 30842774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.
    Noonan KA; Huff CA; Davis J; Lemas MV; Fiorino S; Bitzan J; Ferguson A; Emerling A; Luznik L; Matsui W; Powell J; Fuchs E; Rosner GL; Epstein C; Rudraraju L; Ambinder RF; Jones RJ; Pardoll D; Borrello I
    Sci Transl Med; 2015 May; 7(288):288ra78. PubMed ID: 25995224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular immunotherapy of cancer: an overview and future directions.
    Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
    Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
    Spranger S; Dai D; Horton B; Gajewski TF
    Cancer Cell; 2017 May; 31(5):711-723.e4. PubMed ID: 28486109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic Barriers to T Cell Function in Tumors.
    Sugiura A; Rathmell JC
    J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
    Li H; Zhao Y
    Protein Cell; 2017 Aug; 8(8):573-589. PubMed ID: 28434147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vascular Microenvironment, Tumor Immunity and Immunotherapy.
    Lamplugh Z; Fan Y
    Front Immunol; 2021; 12():811485. PubMed ID: 34987525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy.
    Innamarato P; Kodumudi K; Asby S; Schachner B; Hall M; Mackay A; Wiener D; Beatty M; Nagle L; Creelan BC; Sarnaik AA; Pilon-Thomas S
    Mol Ther; 2020 Oct; 28(10):2252-2270. PubMed ID: 32615068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
    Spranger S
    Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MR1-restricted T cells: the new dawn of cancer immunotherapy.
    Wang Z; Wang M; Chen J; Zhang L; Zhang L; Yu L
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33185693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Engineering T cells for cancer: our synthetic future.
    Vonderheide RH; June CH
    Immunol Rev; 2014 Jan; 257(1):7-13. PubMed ID: 24329786
    [No Abstract]   [Full Text] [Related]  

  • 56. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.
    Nesbeth Y; Conejo-Garcia JR
    Clin Dev Immunol; 2010; 2010():139304. PubMed ID: 21076522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells.
    Shrestha B; Zhang Y; Yu B; Li G; Boucher JC; Beatty NJ; Tsai HC; Wang X; Mishra A; Sweet K; Lancet JE; Kelley L; Davila ML
    J Immunother; 2020 Apr; 43(3):79-88. PubMed ID: 31834208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.